UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

Journal of thrombosis and haemostasis, 2013-04, Vol.11 (4), p.670-678

2013

Volltextzugriff (PDF)

Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants

Clinical pharmacology and therapeutics, 2016-08, Vol.100 (2), p.128-130

Lentz, SR

2016

Volltextzugriff (PDF)

ADAMTS13 reduces VWF‐mediated acute inflammation following focal cerebral ischemia in mice

Journal of thrombosis and haemostasis, 2012-08, Vol.10 (8), p.1665-1671

2012

Volltextzugriff (PDF)

Mechanisms of homocysteine‐induced atherothrombosis

Journal of thrombosis and haemostasis, 2005-08, Vol.3 (8), p.1646-1654

LENTZ, S. R.

2005

Volltextzugriff (PDF)

Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease

Cell death and differentiation, 2004-07, Vol.11 (S1), p.S56-S64

2004

Volltextzugriff (PDF)

Targeting platelet EPCR for better therapeutic factor VIIa activity

Journal of thrombosis and haemostasis, 2018-09, Vol.16 (9), p.1814-1816

2018

Volltextzugriff (PDF)

Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine

The Journal of clinical investigation, 1991-12, Vol.88 (6), p.1906-1914

1991

Volltextzugriff (PDF)

Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-07, Vol.20 (4), p.527-534

2014

Volltextzugriff (PDF)

Comparison of clot‐based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study

Journal of thrombosis and haemostasis, 2013-07, Vol.11 (7), p.1300-1309

2013

Volltextzugriff (PDF)

Clinical and laboratory phenotype variability in type 2M von Willebrand disease

Journal of thrombosis and haemostasis, 2017-08, Vol.15 (8), p.1559-1566

2017

Volltextzugriff (PDF)

Critical von Willebrand factor A1 domain residues influence type VI collagen binding

Journal of thrombosis and haemostasis, 2012-07, Vol.10 (7), p.1417-1424

2012

Volltextzugriff (PDF)

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.1989-1998

2015

Volltextzugriff (PDF)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

Journal of thrombosis and haemostasis, 2014-08, Vol.12 (8), p.1244-1253

2014

Volltextzugriff (PDF)

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-09, Vol.19 (5), p.691-697

2013

Volltextzugriff (PDF)

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors

Journal of thrombosis and haemostasis, 2017-10, Vol.15 (10), p.1971-1976

2017

Volltextzugriff (PDF)

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-01, Vol.21 (1), p.34-40

2015

Volltextzugriff (PDF)

Haemophilia clinical care and research needs: Assessing priorities

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.e270-e273

2018

Volltextzugriff (PDF)

D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment

Thrombosis research, 2016-10, Vol.146, p.119-125

2016

Volltextzugriff (PDF)

Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-09, Vol.22 (5), p.e445-e449

2016

Volltextzugriff (PDF)

Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-09, Vol.21 (5), p.e436-e439

2015

Volltextzugriff (PDF)

Regulation of Thrombomodulin by Tumor Necrosis Factor-α: Comparison of Transcriptional and Posttranscriptional Mechanisms

Blood, 1991-02, Vol.77 (3), p.542-550

1991

Volltextzugriff (PDF)

Homocysteine Inhibits von Willebrand Factor Processing and Secretion by Preventing Transport From the Endoplasmic Reticulum

Blood, 1993-02, Vol.81 (3), p.683-689

1993

Volltextzugriff (PDF)

Homocysteine and its disulfide derivatives: a suggested consensus terminology

Arteriosclerosis, thrombosis, and vascular biology, 2000-07, Vol.20 (7), p.1704-1706

2000

Volltextzugriff (PDF)

Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity

The Journal of biological chemistry, 1992-03, Vol.267 (9), p.6164-6170

1992

Volltextzugriff (PDF)

Single Amino Acid Substitutions Dissociate Fibrinogen-Clotting and Thrombomodulin-Binding Activities of Human Thrombin

Proceedings of the National Academy of Sciences - PNAS, 1991-08, Vol.88 (15), p.6775-6779

1991

Volltextzugriff (PDF)

1 – 25 von 1.966

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.736)
Mit Volltextzugriff
(1.536)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.157)
Life Sciences & Biomedicine
(758)
Humans
(441)
Physical Sciences
(342)
Animals
(316)
Biological And Medical Sciences
(249)
Female
(213)
Male
(207)
Medical Sciences
(138)
Adult
(136)
Hematology
(130)
Biochemistry & Molecular Biology
(126)
Middle Aged
(126)
Technology
(125)
Igneous Rocks
(120)
Fundamental And Applied Biological Sciences. Psychology
(119)
Metal Ores
(112)
Cardiovascular System & Cardiology
(111)
Mice
(105)
Mineralogy
(105)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants

ADAMTS13 reduces VWF‐mediated acute inflammation following focal cerebral ischemia in mice

Mechanisms of homocysteine‐induced atherothrombosis

Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease

Targeting platelet EPCR for better therapeutic factor VIIa activity

Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine

Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa

Comparison of clot‐based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study

Clinical and laboratory phenotype variability in type 2M von Willebrand disease

Critical von Willebrand factor A1 domain residues influence type VI collagen binding

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials

Haemophilia clinical care and research needs: Assessing priorities

D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment

Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

Regulation of Thrombomodulin by Tumor Necrosis Factor-α: Comparison of Transcriptional and Posttranscriptional Mechanisms

Homocysteine Inhibits von Willebrand Factor Processing and Secretion by Preventing Transport From the Endoplasmic Reticulum

Homocysteine and its disulfide derivatives: a suggested consensus terminology

Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity

Single Amino Acid Substitutions Dissociate Fibrinogen-Clotting and Thrombomodulin-Binding Activities of Human Thrombin

Suchergebnisse filtern